* Cidara Therapeutics Inc is expected to show a fall in quarterly revenue when it reports results on October 31 (estimated) for the period ending September 30 2024
* The San Diego California-based company is expected to report a 96.6% decrease in revenue to $433.33 thousand from $12.72 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Cidara Therapeutics Inc is for a loss of $4.25 per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Cidara Therapeutics Inc is 25.00, above its last closing price of $12.47.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jan. 1 0001 -4.01 -3.22 -1.39 Beat 56.9
Jan. 1 0001 -0.20 -0.20 -2.28 Missed -1,040
Jan. 1 0001 -2.07 -0.80 Beat 61.3
Sep. 30 2023 -3.19 -3.25 -1.80 Beat 44.6
Mar. -2.04 -0.73 -2.80 Missed -7.7
31 2023
Mar. 31 2023 -0.41 -0.73 0.60 Beat 181.8
Jan. 1 0001 -4.24 -3.35 -3.80 Missed -13.4
Sep. 30 2022 3.71 3.60 3.40 Missed -5.6
This summary was machine generated October 29 at 11:17 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments